Clairvest Re-Enters Life Sciences Industry with Investment in Boca Biolistics
21 Februar 2023 - 11:00PM
Clairvest Group Inc. (TSX: CVG) (“CVG”) today announced that it,
together with Clairvest Equity Partners VI (“CEP VI”, collectively
“Clairvest”) has made a US$25 million equity investment in Boca
Biolistics (“Boca” or the “Company”), partnering with its
management team for the next phase of growth.
Founded in 2007, Boca Biolistics is a leading
clinical research organization and biomaterials company focused on
the procurement, storage, and sale of human biological samples
(specializing in infectious diseases and oncology) used for
clinical trials and diagnostic development. Boca has a strong
reputation as a trusted vendor in the industry and sources samples
from its proprietary network of collection sites internationally.
The Company also offers in-house analytical laboratory testing and
characterization services for internal and third-party samples.
Going forward, Boca will be led by two of its founders, Valentin
Adia (CEO) and Michael Morris (COO), both of whom have rolled a
significant portion of their equity alongside Clairvest. Boca
Biolistics represents Clairvest’s second investment in the life
sciences domain.
“Our investment in Boca is the result of a
multi-year domain effort in the life sciences industry and
represents a compelling opportunity to back an entrepreneurial
management team. Boca plays an important role in advancing the
development of novel pharmaceutical drugs and diagnostic devices
and we are delighted to partner with Valentin and Michael,” said
Sebastien Dhonte, Managing Director of Clairvest.
“We chose to partner with Clairvest because we
believe in their partnership-oriented investment style and their
ability to help us accelerate our growth over the coming years. We
are excited to build on Boca Biolistics’ track record as a leading
provider of biosamples and support important biopharma and
diagnostic research & development efforts,” said Valentin Adia,
CEO of Boca Biolistics.
The Boca Biolistics investment is Clairvest’s
60th platform investment and 9th investment in the Clairvest / CEP
VI co-investment pool which is capitalized at US$850 million.
About ClairvestClairvest’s
mission is to partner with entrepreneurs to help them build
strategically significant businesses. Founded in 1987 by a group of
successful Canadian entrepreneurs, Clairvest is a top performing
private equity management firm with over CAD $3.3 billion of
capital under management. Clairvest invests its own capital and
that of third parties through the Clairvest Equity Partners limited
partnerships in owner-led businesses. Under the current management
team, Clairvest has initiated investments in 60 different platform
companies and generated top quartile performance over an extended
period.
Contact InformationStephanie
LoManager, Investor Relations and MarketingClairvest Group Inc.Tel:
(416) 925-9270stephaniel@clairvest.com
Clairvest (TSX:CVG)
Historical Stock Chart
Von Okt 2024 bis Nov 2024
Clairvest (TSX:CVG)
Historical Stock Chart
Von Nov 2023 bis Nov 2024